TY - JOUR
T1 - The services for children and adolescents-parent interview
T2 - Development and performance characteristics
AU - Jensen, Peter S.
AU - Hoagwood, Kimberly Eaton
AU - Roper, Margaret
AU - Arnold, L. Eugene
AU - Odbert, Carol
AU - Crowe, Maura
AU - Molina, Brooke S.G.
AU - Hechtman, Lily
AU - Hinshaw, Stephen P.
AU - Hoza, Betsy
AU - Newcorn, Jeffrey
AU - Swanson, James
AU - Wells, Karen
N1 - Funding Information:
The SCAPI was developed through a cooperative agreement funded by the National Institute of Mental Health. It cannot be copyrighted and is in the public domain. It can be obtained online at www.jaacap.com via the Journal's Article Plus feature, where the SCAPI interview and supplementary materials are available. Current information about training and certification can be obtained by contacting Carol Odbert at NIMH ( [email protected] ) or the first author ( [email protected] ).
Funding Information:
Disclosure: Dr. Jensen has research grants from Janssen Pharmaceutical and McNeil Pharmaceuticals; is a consultant/advisor to Shire, Celltech, Janssen, McNeil, Pfizer, Novartis, and Lilly; and is on the Speaker's Bureau of Phase V, CME Outfitters, and REACH. Dr. Arnold has research funding from Celgene, Shire, Lilly, Noven, Sigma Tau, Targacept, and Novartis; is a consultant/advisor to Shire, Sigma Tau, and Noven; and is on the Speakers’ Bureau of Shire, McNeil, Lilly, and Novartis. Dr. Hechtman has research funding from Eli Lilly, GlaxoSmithKline, Janssen Ortho, Purdue, and Shire and is on the Advisory Board of Eli Lilly, Janssen Ortho, Purdue, and Shire. In addition, she is a speaker for Janssen Ortho and Shire. Dr. Hinshaw is a consultant for Sigma Tau and is on the Speakers’ Bureau of McNeil. Dr. Newcorn has research grants from Eli Lilly and Shire and is an advisor for Eli Lilly, McNeil, Novartis, and Shire and a consultant for Eli Lilly. His continuing medical education and other educational activities involve Eli Lilly, Janssen, McNeil, and Novartis. Dr. Swanson has support from several pharmaceutical companies, including contracts, grants, consultation, and positions on the Advisory Board and Speaker's Bureau of McNeil, Janssen, Celltech, Shire, Novartis, Lilly, and Cephalon.
PY - 2004/11
Y1 - 2004/11
N2 - Objective: To date, no instrument has been developed that captures children's services use across primary care, specialty mental health, and other settings, including setting, treatment type, provider discipline, and length and intensity of specific interventions over varying follow-up periods. The authors developed a highly structured services assessment measure [Services for Children and Adolescents-Parent Interview (SCAPI)] for use in the National Institute of Mental Health Multimodal Treatment Study of Children With Attention Deficit Hyperactivity Disorder (MTA). Method: After successfully piloting and refining the SCAPI during initial phases of the MTA, the authors used this measure at 24 months post-randomization to ascertain the previous 6 months of services use for all participating (516 of 579) MTA children and families and 285 age- and gender-matched classroom control children. Results: Findings revealed meaningful, face-valid differences between MTA and control children in levels and types of services used during the previous 6-month period. Services use data reported by parents was substantially in accord with data independently gathered by the research data center. Site variations were found in the level and use of several specific services, such as individual child psychotherapy (sites ranged from 0% to 6.8% among classroom controls compared with 9.7% to 46.1% among MTA participants) and special education services (0% to 14.6% among classroom controls, 27.5% to 34.8% among MTA participants), consistent with differences reported in other studies. Conclusions: These data support the descriptive validity of SCAPI-ascertained services use data and indicate that the SCAPI can provide investigators and policymakers a valid means of assessing services type, intensity, onset and offset, provider type, and content.
AB - Objective: To date, no instrument has been developed that captures children's services use across primary care, specialty mental health, and other settings, including setting, treatment type, provider discipline, and length and intensity of specific interventions over varying follow-up periods. The authors developed a highly structured services assessment measure [Services for Children and Adolescents-Parent Interview (SCAPI)] for use in the National Institute of Mental Health Multimodal Treatment Study of Children With Attention Deficit Hyperactivity Disorder (MTA). Method: After successfully piloting and refining the SCAPI during initial phases of the MTA, the authors used this measure at 24 months post-randomization to ascertain the previous 6 months of services use for all participating (516 of 579) MTA children and families and 285 age- and gender-matched classroom control children. Results: Findings revealed meaningful, face-valid differences between MTA and control children in levels and types of services used during the previous 6-month period. Services use data reported by parents was substantially in accord with data independently gathered by the research data center. Site variations were found in the level and use of several specific services, such as individual child psychotherapy (sites ranged from 0% to 6.8% among classroom controls compared with 9.7% to 46.1% among MTA participants) and special education services (0% to 14.6% among classroom controls, 27.5% to 34.8% among MTA participants), consistent with differences reported in other studies. Conclusions: These data support the descriptive validity of SCAPI-ascertained services use data and indicate that the SCAPI can provide investigators and policymakers a valid means of assessing services type, intensity, onset and offset, provider type, and content.
KW - Attention-deficit/ hyperactivity disorder
KW - Interviews
KW - Mental health services
KW - Services research
KW - Services use
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=6944253486&partnerID=8YFLogxK
U2 - 10.1097/01.chi.0000139557.16830.4e
DO - 10.1097/01.chi.0000139557.16830.4e
M3 - Article
AN - SCOPUS:6944253486
SN - 0890-8567
VL - 43
SP - 1334
EP - 1344
JO - Journal of the American Academy of Child and Adolescent Psychiatry
JF - Journal of the American Academy of Child and Adolescent Psychiatry
IS - 11
ER -